Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake
Journal of the Endocrine Society · 05.06.2023 · 7 (7)
DOI: 10.1210/jendso/bvad074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 07.06.2023. Verfasst von Carolina R Cawthon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology and Program in Neuroscience, Florida State University, Tallahassee, FL 32306, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIDCD NIH HHS, NIH.
Abstract (Originalsprache)
Context
The glucagon-like peptide-1 receptor (GLP-1R) agonist semaglutide (SEMA) produces 15% weight loss when chronically administered to humans with obesity.
Methods
In 2 separate experiments, rats received daily injections of either vehicle (VEH) or SEMA starting at 7 µg/kg body weight (BW) and increasing over 10 days to the maintenance dose (70 µg/kg-BW), emulating clinical dose escalation strategies.
Results
During dose escalation and maintenance, SEMA rats reduced chow intake and bodyweight. Experiment 2 meal pattern analysis revealed that meal size, not number, mediated these SEMA-induced changes in chow intake. This suggests SEMA affects neural processes controlling meal termination and not meal initiation. Two-bottle preference tests (vs water) began after 10 to 16 days of maintenance dosing. Rats received either an ascending sucrose concentration series (0.03-1.0 M) and 1 fat solution (Experiment 1) or a 4% and 24% sucrose solution in a crossover design (Experiment 2). At lower sucrose concentrations, SEMA-treated rats in both experiments drank sometimes >2× the volume consumed by VEH controls; at higher sucrose concentrations (and 10% fat), intake was similar between treatment groups. Energy intake of SEMA rats became similar to VEH rats. This was unexpected because GLP-1R agonism is thought to decrease the reward and/or increase the satiating potency of palatable foods. Despite sucrose-driven increases in both groups, a significant bodyweight difference between SEMA- and VEH-treated rats remained.
Conclusion
The basis of the SEMA-induced overconsumption of sucrose at lower concentrations relative to VEH controls remains unclear, but the effects of chronic SEMA treatment on energy intake and BW appear to depend on the caloric sources available.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychology and Program in Neuroscience, Florida State University, Tallahassee, FL 32306, USA.
- Diabetes Complications Research Center, Conway Institute, School of Medicine, University College Dublin, Dublin, D04 C1P1, Ireland.
ORCID-Profile: Alan C Spector
Förderung
- NIDDK NIH HHS
- NIDCD NIH HHS
- NIH
- NIH/NIDCD
- Florida State University Bridge Funds
Zitieren
APA
Cawthon, C. R., Blonde, G. D., Nisi, A. V., Bloomston, H. M., Krubitski, B., le Roux, C. W., & Spector, A. C. (2023). Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake. Journal of the Endocrine Society, 7(7). https://doi.org/10.1210/jendso/bvad074
Vancouver
Cawthon CR, Blonde GD, Nisi AV, Bloomston HM, Krubitski B, le Roux CW, et al. Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake. Journal of the Endocrine Society. 2023;7(7). doi:10.1210/jendso/bvad074
BibTeX
@article{Cawthon2023,
author = {Cawthon, Carolina R and Blonde, Ginger D and Nisi, A Valentina and Bloomston, Haley M and Krubitski, Belle and le Roux, Carel W and Spector, Alan C},
title = {Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake},
journal = {Journal of the Endocrine Society},
year = {2023},
volume = {7},
number = {7},
doi = {10.1210/jendso/bvad074}
}
EUVIMED